MedTrace Logo

Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients

NCT03390322 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2024-12-18

No results posted yet for this study

Summary

This is a multi-center, prospective, open label study of the Duodenal Glycemic Control™ procedure on type 2 diabetes patients sub-optimally controlled, to examine the safety and initial performance of the DiaGone™ system.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

DiaGone™

Duodenal Glycemic Control™ using the DiaGone™ system

Sponsors & Collaborators

  • Digma Medical Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-28
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Czechia
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03390322 on ClinicalTrials.gov